Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's DiseaseGlobeNewsWire • 12/05/23
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original ProjectionsGlobeNewsWire • 11/27/23
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/08/23
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer's Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)Business Wire • 10/30/23
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease ConferenceBusiness Wire • 10/24/23
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's StudyGlobeNewsWire • 10/12/23
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateBusiness Wire • 08/15/23
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International ConferenceBusiness Wire • 07/18/23
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson's Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)Business Wire • 06/20/23
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record PacePRNewsWire • 06/08/23
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23
Wall Street Analysts See a 213.78% Upside in Annovis Bio, Inc. (ANVS): Can the Stock Really Move This High?Zacks Investment Research • 05/04/23
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick HumansGlobeNewsWire • 04/27/23